A股異動 | 科興製藥(688136.SH)大漲逾12% 與安泰維合作開發抗新冠病毒藥物
格隆匯2月21日丨科興製藥(688136.SH)競價漲停,現漲幅回落至12.16%,報29.42元,成交額放大至1.29億元,總市值58.42億元。公司20日晚公吿稱,公司全資子公司深圳科興與深圳安泰維生物醫藥有限公司簽署《SHEN26項目合作協議》。SHEN26是用於治療新冠及其他病毒感染的抗病毒藥物,已被列入2021年度廣東省防控新型冠狀病毒感染科技攻關應急專項,是國家科學技術部公共安全風險防控與應急技術裝備專項重點推動項目 。本次合作協議的簽署將進一步加快公司創新藥佈局,增厚產品儲備,增強公司核心競爭力,豐富公司抗病毒產品管線。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.